Vgl-2 Inhibitors
Chemical inhibitors of Vgl-2 can modulate its activity through various cellular signaling pathways. The compound Y-27632 is known to be a ROCK inhibitor, directly affecting the RhoA/ROCK pathway, which plays a significant role in cytoskeletal organization. Inhibition of ROCK by Y-27632 leads to a relaxation of the cytoskeleton, thereby impacting Vgl-2's function related to cellular structure and mechanics. Similarly, PD98059 and U0126 function as MEK inhibitors, which obstruct the MAPK/ERK pathway. This pathway is crucial for the regulation of transcription factors and cellular responses to external stimuli. By preventing the activation of MEK, these inhibitors indirectly impair the transcriptional activity where Vgl-2 is involved, thereby modulating its role in the cell. The PI3K inhibitors LY294002 and Wortmannin prevent the activation of Akt, a central kinase in many signaling pathways. Given that Vgl-2 interacts with elements regulated by Akt, its functional participation in processes governed by PI3K/Akt signaling is inhibited.
Furthermore, SB203580 and SP600125 target the p38 MAPK and JNK signaling pathways, respectively. SB203580, as a p38 MAPK inhibitor, affects Vgl-2's role in stress responses and inflammation by blocking this specific MAPK pathway, which Vgl-2 is thought to be involved in. On the other hand, SP600125 inhibits the JNK pathway, potentially impacting Vgl-2's function in the signaling cascades regulated by JNK. Another dimension of regulation is provided by Rapamycin, which inhibits mTOR, a key component of cell growth and proliferation pathways. The inhibition of mTOR by Rapamycin leads to the modulation of Vgl-2's involvement in these cellular processes. PKC inhibitors, such as GF109203X and Go6983, impede protein kinase C pathways, to which Vgl-2's function is also linked. By inhibiting PKC, these compounds affect the signaling pathways that Vgl-2 participates in. Lastly, ZM336372 and SL327 specifically inhibit Raf-1 and MEK, respectively, both of which are upstream regulators of ERK in the MAPK/ERK signaling pathway. By inhibiting these kinases, these chemicals regulate Vgl-2's role in the pathway, thus modulating its overall function within the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
This chemical is a ROCK inhibitor, which can inhibit the RhoA/ROCK pathway. Vgl-2 is implicated in cytoskeletal organization, and inhibition of ROCK would lead to relaxation of the cytoskeleton, potentially inhibiting the function of Vgl-2 in maintaining cellular structure. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
As an inhibitor of MEK, PD98059 blocks the MAPK/ERK pathway. Vgl-2 has been associated with the regulation of transcription factors modulated by this pathway. Inhibition of MEK thus can inhibit the downstream transcriptional activity where Vgl-2 may be involved. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
This is a PI3K inhibitor, which prevents the phosphorylation and activation of Akt, a kinase involved in numerous cellular processes. Since Vgl-2 is known to interact with components regulated by Akt signaling, inhibiting PI3K can inhibit the signaling pathways that Vgl-2 may influence. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
This compound is a p38 MAPK inhibitor, which can inhibit the p38 MAPK pathway. Vgl-2's function in stress responses and inflammation can be inhibited by obstructing the p38 MAPK pathway, affecting the cellular processes Vgl-2 is involved in. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, SP600125 can inhibit the JNK signaling pathway. Vgl-2 is known to be involved in pathways that are regulated by JNK, and inhibiting this kinase can inhibit those pathways, thus inhibiting Vgl-2's function in these signaling cascades. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
This chemical inhibits MEK1/2, which are upstream regulators of the ERK pathway. Since Vgl-2 is implicated in cellular processes that are regulated by ERK, inhibition of MEK1/2 can inhibit the function of Vgl-2 in these processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A potent inhibitor of PI3K, Wortmannin can inhibit cellular processes that are regulated by PI3K/Akt signaling. Vgl-2, which may be involved in these processes, can be functionally inhibited by the obstruction of this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
By inhibiting mTOR, Rapamycin can inhibit downstream signaling pathways involved in cell growth and proliferation. As Vgl-2 is implicated in those cellular processes, inhibition of mTOR can functionally inhibit the role of Vgl-2 in these pathways. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
This compound is a PKC inhibitor, which can inhibit protein kinase C pathways. As Vgl-2 is implicated in pathways that involve PKC, inhibiting PKC can inhibit the signaling pathways that Vgl-2 is part of, thus inhibiting its function. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
Another PKC inhibitor, Go6983, can inhibit the function of Vgl-2 by inhibiting the PKC pathways that Vgl-2 may regulate or be influenced by, thus affecting its functional role in the cell. | ||||||